Quantcast

Drug Fails To Benefit Patients With Kidney Disease

October 31, 2011

(Ivanhoe Newswire) — A drug meant to be beneficial, is suddenly found not so useful.  According to a study, the drug sulodexide that was hoped to be a promising new drug to protect the kidneys has failed to benefit diabetes patients with kidney disease.

The drug sulodexide is actually a naturally occurring compound had has been used for more than 20 years to treat various heart conditions.  Previous research indicates that sulodexide reduces excretion of protein in the urine, which is a hallmark of kidney disease.

David Packham, M.D, Melbourne Renal Research Group, Australia, and his colleagues within the Collaborative Study Group, a large clinical trial group comprised of various kidney care centers, conducted a randomized placebo-controlled study in patients with diabetes and kidney disease. The investigators planned to enroll 2,240 patients in the Sun-MACRO trial over a period of two years, but they stopped the study early after enrolling 1,248 patients because they did not detect any significant differences between sulodexide and placebo for preventing kidney failure. Also, the trial did not confirm the potentially beneficial effect of sulodexide in reducing urinary protein excretion that was previously reported in smaller studies.

“In view of the negative results of Sun-MICRO trial and the data analysis from this study, it is tempting to conclude that sulodexide has no therapeutic benefit in type 2 diabetic nephropathy,” the authors wrote.

Kidney disease due to diabetes is the most common cause of kidney failure in developed countries. The number of patients with type 2 diabetes is expected to double and reach 366 million individuals worldwide by 2030.

SOURCE: Journal of the American Society Nephrology




comments powered by Disqus